Cargando…

CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression

SIMPLE SUMMARY: Glioblastoma is the most common brain cancer, and prognosis remains dismal. Continued efforts to find better treatments have shown the promise of immunotherapy, whereby the immune response against a tumor is augmented. One particular immunotherapy, CAR T therapy, involves engineering...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luksik, Andrew S., Yazigi, Eli, Shah, Pavan, Jackson, Christopher M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000604/ https://www.ncbi.nlm.nih.gov/pubmed/36900205 http://dx.doi.org/10.3390/cancers15051414

Ejemplares similares

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers
por: Kailayangiri, Sareetha, et al.
Publicado: (2020)

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Gene Targets of CAR-T Cell Therapy for Glioblastoma
por: Wang, Chaoqun, et al.
Publicado: (2023)

Overcoming tumor resistance mechanisms in CAR-NK cell therapy
por: Valeri, Antonio, et al.
Publicado: (2022)

CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
por: Guedan, Sonia, et al.
Publicado: (2018)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
por: Xia, An-Liang, et al.
Publicado: (2017)

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
por: Larson, Rebecca C., et al.
Publicado: (2023)

Prospective approaches to enhancing CAR T cell therapy for glioblastoma
por: Choi, Sun Il, et al.
Publicado: (2022)

Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier
por: Sharma, Rohit K., et al.
Publicado: (2021)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead
por: Soltantoyeh, Tahereh, et al.
Publicado: (2021)

Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
por: Garzon-Muvdi, Tomas, et al.
Publicado: (2018)

IM-7 Identification of novel glioblastoma specific antigen using patient derived tumor cell for CAR-T cell therapy
por: Nakagawa, Tomoyoshi, et al.
Publicado: (2021)

Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma
por: Liang, Tingyu, et al.
Publicado: (2023)

Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
por: Masoumi, Javad, et al.
Publicado: (2021)

CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023)

Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
por: Song, Moo-Kon, et al.
Publicado: (2019)

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
por: Sun, Shangjun, et al.
Publicado: (2018)

Overcoming Challenges With Statin Therapy
por: Spence, J. David, et al.
Publicado: (2016)

Targeting Tumor-Associated Antigen: A Promising CAR-T Therapeutic Strategy for Glioblastoma Treatment
por: Zhu, Guidong, et al.
Publicado: (2021)

Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors
por: Mi, Juan, et al.
Publicado: (2022)

DDRE-24. TARGETING PURINE METABOLISM TO OVERCOME GLIOBLASTOMA THERAPY RESISTANCE
por: Zhou, Weihua, et al.
Publicado: (2021)

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
por: Yan, Ting, et al.
Publicado: (2023)

Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence
por: Satterlee, Andrew B., et al.
Publicado: (2022)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Navigating the Immune Challenge in Glioblastoma: Exploring Immunotherapeutic Avenues for Overcoming Immune Suppression
por: Jain, Prateek, et al.
Publicado: (2023)

BSCI-19 A LENTIVIRAL CRISPR SCREEN FOR EPIGENETIC MODULATORS OF ANTIGENS TARGETED BY CAR T CELLS IN GLIOBLASTOMA
por: Jordan Walter, T, et al.
Publicado: (2022)

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas
por: Wang, Chun, et al.
Publicado: (2023)

How Can We Engineer CAR T Cells to Overcome Resistance?
por: Glover, Maya, et al.
Publicado: (2021)

P1464: DECREASING HPK1 EXPRESSION IN CD19 CAR-T CELLS: A NOVEL STRATEGY TO OVERCOME CHALLENGES OF CELL THERAPY FOR ADULT (R/R) B-ALL
por: ZHANG, N., et al.
Publicado: (2022)

Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors
por: Wang, Yufeng, et al.
Publicado: (2023)

CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma
por: Maggs, Luke, et al.
Publicado: (2021)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
por: Klampatsa, Astero, et al.
Publicado: (2017)

Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapies for the Treatment of Primary Brain Tumors
por: Mount, Christopher W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2mnv7q3ca0hpl7gc16g47823fm